Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MICHAEL E. STEUER MD PC

NPI: 1124348545 · OXFORD, MS 38655 · Specialist · NPI assigned 06/08/2010

$234K
Total Medicaid Paid
13,204
Total Claims
11,956
Beneficiaries
9
Codes Billed
2018-01
First Month
2024-11
Last Month

Provider Details

Authorized OfficialSTEUER, MICHAEL (PRESIDENT/CEO)
NPI Enumeration Date06/08/2010

Related Entities

Other providers sharing the same authorized official: STEUER, MICHAEL

ProviderCityStateTotal Paid
MICHAEL E STEUER, MD, PC CORDOVA TN $2.63M
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC GERMANTOWN TN $2.08M
MICHAEL E STEUER MD PC JACKSON TN $1.02M
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC SOUTHAVEN MS $742K
MICHAEL E STEUER MD PC SOUTHAVEN MS $637K
MICHAEL E STEUER MD PC TUPELO MS $266K
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC JACKSON TN $252K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 2,650 $32K
2019 2,663 $48K
2020 2,093 $41K
2021 2,211 $43K
2022 2,409 $46K
2023 685 $14K
2024 493 $10K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 4,445 4,046 $87K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 2,598 2,311 $51K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,455 2,239 $27K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 725 638 $20K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 505 479 $19K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 349 309 $16K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,142 1,055 $12K
80305 949 844 $1K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 36 35 $1K